Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using latanoprost for hair loss treatment. Participants also mention Minoxidil, finasteride, and RU58841 as other treatments.

The conversation discusses a user's three-month progress using topical finasteride once a day, 6% minoxidil at night, and weekly dermastamping at 1.25mm for hair loss. Commenters note the impressive results and discuss application methods and safety precautions for family members.

The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A user experienced side effects from hair loss treatment and contacted HIMS, resulting in their subscription being canceled. They were taking Zinc to manage symptoms and are considering consulting a doctor.

The user is exploring topical Saw Palmetto as a milder alternative to microdosing topical Finasteride for hair loss, aiming to minimize systemic DHT impact. They plan to experiment with this herbal remedy for a year to assess its effectiveness on their mild androgenetic alopecia without significant side effects.

A user with androgenetic alopecia is using 8 ml of 1.4% topical spironolactone solution daily but is unsure if this amount is excessive, as 2 ml is more typical. They seek advice on the appropriate amount to apply.

Hair loss progress discussed, treatments used include oils, scalp massages, serenoa pills, and dermastamp. User asks for advice without mentioning minoxidil or finasteride.

The conversation discusses using 23andme to determine if someone might respond well to minoxidil for hair loss treatment, and mentions the user's personal experience with micro-needling and minoxidil.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.

The user is pleased with their hair transplant results after six months and seeks feedback. The conversation is positive, with others affirming the success of the procedure.

A dermatologist prescribed oral minoxidil, finasteride, and spironolactone, suggesting minoxidil and finasteride as the most effective combination, but with potential side effects. Another user recommended minoxidil (both topical and oral) and spironolactone for female hair loss, advising against finasteride.

The conversation humorously discusses various methods of applying minoxidil for hair loss, with some users suggesting oral minoxidil as a more convenient option despite potential side effects. The original poster jokes about using a red light helmet with mesotherapy needles for continuous minoxidil application.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

The user is considering a second hair transplant or scalp micropigmentation to address thinning in the crown area and hide scars from a previous transplant. They have been using finasteride and minoxidil for three years but are concerned about the appearance of their donor area and the effectiveness of scalp micropigmentation.

The conversation is a satirical expression of frustration over hair loss, mentioning treatments like spironolactone, microneedling, and topical applications, with references to various hair loss products and personalities in the community.

The conversation discusses the effectiveness of commercial Low-Level Laser Therapy (LLLT) devices for hair growth, suggesting they are underpowered compared to the ideal energy output shown in medical research. A user plans to build a custom helmet that meets the required specifications for effective treatment.

A 30-year-old man is considering quitting Finasteride due to sexual side effects, including reduced libido and difficulty reaching orgasm, despite its effectiveness in treating hair loss. He is exploring other factors like relationship issues and potential low testosterone, and is considering getting blood work done.

The conversation discusses hair loss treatments using oral minoxidil, oral dutasteride, and mesotherapy dutasteride, showing impressive 6-month results. The user wishes these treatments were available in the U.S.

A user from India discusses using a topical solution containing Minoxidil (50mg) and Finasteride (1mg) twice a day for thinning hair and Norwood 2/3. The dermatologist recommended it for maintenance with slim chances of regrowth, and the user seeks advice on its use.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.

The conversation is about a user's 26-month hair loss treatment journey using finasteride, minoxidil foam, and microneedling, with gradual improvement in their hairline. The user applied treatments consistently and adjusted the frequency of microneedling based on feedback, noting that progress can feel slow compared to others.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

The user, Salty-Peace-577, shared their 5-month update on using 0.5mg oral finasteride and 2.5mg oral minoxidil for hair loss. They experienced significant hair growth, particularly in their eyebrows, and shared their regimen and tips for hair growth. Some users in the conversation also discussed the side effects they experienced with different dosages of the medications.

Clascoterone 5% shows potential for hair thickening and darkening, especially when combined with treatments like finasteride. It may be a good alternative for those who experience side effects from other treatments.

The user added melatonin to their 5% minoxidil solution for hair growth, using a concentration of 0.0033%, which equates to roughly 2mg for a 60ml bottle. They later reported no significant difference and planned to continue the treatment for a few more months before potentially stopping to observe any changes in shedding.

The user is considering taking 2.5 mg oral minoxidil and 1 mg oral finasteride sublingually to minimize side effects after a hair transplant. They seek advice on the pros and cons of this method, noting a lack of concrete information.

The conclusion of the conversation is that some users have seen positive results with the use of finasteride and minoxidil for hair loss, while others have not. It is mentioned that consistent use of these treatments is necessary to maintain results.